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EDITORIAL REVIEW
Neoplasia and glomerular injury
The development of several types of glomerular injury in
patients with cancer has been recognized for over two decades,
and indeed is now considered as one of the paraneoplastic
syndromes [1—3]. When the subject was last reviewed in this
journal, several associations between glomerulopathy and
neoplasia were noted. Most prominent were the occurrence of
membranous glomerulonephritis in patients with carcinoma,
and the association between minimal change glomerulopathy
and Hodgkin's disease [I]. Although these associations have
since been supported by reports of patients with malignancy in
whom the activity of the renal lesion closely corresponded to
the activity of the tumor [4—9], studies of large series of patients
with cancer or glomerular disease have tended to minimize the
frequency or importance of these associations [10—121.
In this review we provide an update of the published work on
this issue and attempt to answer three questions which remain
relevant today. 1) How strong is the association between
specific glomerular lesions, such as, membranous glomerulone-
phritis and carcinoma, and minimal change disease and
lymphoproliferative disorders? 2) To what extent should pa-
tients presenting with idiopathic nephrotic syndrome be evalu-
ated for occult malignancy? 3) What is known of the pathogen-
esis of glomerular injury in patients with cancer, and to what
extent can the glomerular disease be attributed to immune
responses to tumor—related antigens or to a defect in immune
regulation in these patients?
Membranous glomerulonephritis and carcinomas
In a literature survey, Eagen and Lewis collected 67 cases of
carcinoma associated with the nephrotic syndrome and found
that 33 of 48 in whom renal tissue was examined had membra-
nous glomerulopathy (MGN) as the underlying renal lesion [1].
Neoplasms that have been implicated include a variety of
histologic types from different primary sites, but the largest
number has been carcinomas of the lung and adenocarcinomas
of the gastrointestinal tract [1—5, 7—13]. Although this may be
related to the frequency in which neoplasms arise in these sites,
other sites from which carcinomas commonly arise, such as
breast, have only rarely been associated with specific
glomerulopathies [71.
A widely quoted paper by Lee, Yamauchi and Hopper
reported associated malignancies in 11 of 101 adult patients
(10.9%) with idopathic nephrotic syndrome, with the most
common association being between carcinoma and membra-
nous nephropathy [4]. Subsequently the same authors found
temporally—associated carcinomas in 6% of their series of
membranous glomerulonephritis [14]. Row et al also found
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evidence of malignancy in 10.9% of adult patients with MGN
[15]. These two series of studies have been frequently invoked
to support a search for occult malignancy in all adults with
idiopathic nephrotic syndrome and particularly in those with
MGN. A recent abstract reported that 35% of 40 cases of
membranous nephropathy in adults aged over 60 were associ-
ated with 'another disease which was malignant in 20% of the
cases," but details of this study are not yet available [161.
Others, however, have not confirmed these high incidence
rates. Kaplan, Klassen and Gault found only six cases of
malignancy in a literature review of 14 series of patients with
nephrotic syndrome, which included 1,643 cases, although they
did give consideration to the problem of under—reporting of this
association [17]. Heneghan Ct al specifically studied 89 adult
cases of nephrotic syndrome and found only one case of
associated colonic carcinoma [12]. Pascal et al studied the
kidneys of 29 patients with a variety of neoplasms at autopsy by
means of light, immunofluorescence, and electron microscopy.
They found immune deposits in 22 of 29 cases, but these
deposits were invariably localized to mesangial and subendo-
thelial portions of the glomerulus, and no patients had protein-
uria [18]. Autopsy studies of an additional 27 patients with
bronchial carcinoma [19], 40 patients with renal cell carcinoma
[20], and a biopsy study of 39 patients with unspecified malig-
nancies also failed to confirm a high incidence of MGN [21].
Among this group of patients, two of 27 patients in one series
and four of 39 in another series had a few small subepithelial
dense deposits [19, 21]. None of these patients had proteinuria
and none of the patients with subepithelial deposits who were
studied had demonstrable immunoglobulin deposition by im-
munofluorescence. Not a single case of clinically evident or
subclinical membranous glomerulonephritis was identified in
this group of 125 cases. The studies quoted above provide a
morphologic correlate to serologic studies which show elevated
levels of circulating immune complexes in most patients with
cancer, who typically show no evidence of glomerular disease
[22]. It seems likely that the mesangial and subendothelial
deposits represent either nonspecific trapping of immune com-
plexes, or possibly binding of some tumor antigen to glomerular
structures with subsequent in situ immune complex formation,
but they do not explain why some patients with carcinoma
develop MGN and nephrotic syndrome.
If one considers the incidence of carcinoma in the general
population, it is apparent that the incidence of any associated
glomerular lesion must be rare. While we are reluctant to set
guidelines for the management of individual cases of MGN, we
believe the case for a full malignancy work—up in all adult
patients with this diagnosis may have been overstated. Proce-
dures beyond those which are appropriate for routine cancer
screening based on the patient's age and personal medical
history are not justified by the data now available on this issue.
It is presumed that the glomerular injury in patients with
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cancer and MGN is mediated by immune complexes composed
at least in part of tumor—associated antigens. This is based on
the observation that clinical resolution of the glomerulopathy
follows successful therapy of tumor in some cases, and on the
results of a few studies which have found evidence for
tumor—associated antigens in the glomeruli of affected patients.
However, evidence on both of these issues is equivocal. Al-
though dramatic cases of remission of the ncphrotic syndrome
after resection of the carcinoma have been reported [4, 5,7, 8],
it has also been true that in a number of cases the nephrotic
syndrome has persisted, even in cases where the disappearance
of the subepithelial deposits has been demonstrated in subse-
quent biopsies [231. These cases suggest that remissions of
nephrotic syndrome temporally associated with successful tu-
mor therapy may be due to the waxing and waning clinical
activity characteristic of membranous nephropathy, or alterna-
tively that the deposits seen in some cases of MGN associated
with tumors may be clinically deleterious only in association
with some other nephrotoxic factor. It also seems likely that the
association of persistent nephrotic syndrome in the setting of
malignancy is more likely to be under—reported than the more
striking cases where remission of both appears related.
The demonstration of immunoglobulin and complement in
glomerular lesions and the similarity between the ultrastructural
features of cancer—associated MGN with idiopathic MGN sug-
gest an antibody—mediated glomerular injury, either due to
circulating immune complexes or due to in situ immune com-
plex deposition [24], However, in only a small number of
patients with malignancy—associated membranous nephropathy
has the search for a specific antigen—antibody system been even
partly successful, Using indirect immunofluorescence tech-
niques, antisera reactive with carcinoembryonic antigen (CEA)
or melanoma—associated antigens have been localized to
glomerular capillary walls in a pattern similar to the patient's
own deposited IgG in single cases of colonic carcinoma and
adenocarcinoma of the palate for CEA [25, 26] and malignant
melanoma [271. In these studies, normal control kidneys were
not stained by the antisera, but further attempts to characterize
specific antibody binding to these antigens were not described.
In several other cases, antibody eluted from renal parenchyma
was shown to be reactive with extracts or homogenates of the
patient's tumor. Using this approach, da Costa et al reported
that an eluate of lgG from the kidneys of a patient with
bronchogenic carcinoma was reactive with homogenates of the
lung tumor and normal human lung, but not with normal kidney
[28]. Lewis, Loughridge and Phillips found that eluted renal
antibodies and serum from a patient with bronchial carcinoma
reacted with crude tumor extracts by immunodiffusion tech-
niques [29]. Demonstration of specific antigen—antibody com-
plexes was either not attempted or accomplished in these
studies. Wakashin et al found that antibody eluted from the
kidneys of patients with gastric carcinoma had reactivity with
both the patient's own tumor and with tumor tissue obtained
from a variety of other human gastrointestinal tumors [81. They
also reported evidence for CEA deposition of glomerular cap-
illary walls by an indirect immunofluorescence technique, but
the specificity of their antisera was tested only by its activity
against a variety of normal and neoplastic cell types but not
against purified preparations of CEA.
In a study of a patient with colonic carcinoma and MGN,
Couser et al showed reactivity of patient's serum with the
patient's own glomeruli after appropriate elution of antibody
already bound to the kidney; concurrently, the patient's serum
was also capable of reacting to some tumor—related antigens
present in tumor homogenates, but not in normal colonic tissue
[23]. In this case, elevated serum CEA was present, but no
CEA was demonstrable in glornerular deposits. Elution studies
to characterize activity of the glomerular antibody deposited in
vivo against the tumor homogenates were not performed. All
these approaches provide evidence that is suggestive but incon-
clusive that tumor antigen—associated immune complexes are
the cause of the membranous glomerulonephritis in these pa-
tients. In each of these studies, the question of the specificity of
the deposition versus non-specific trapping of either antigen,
antibody, or complexes is not completely resolved.
Somewhat more convincing evidence of specific tumor—as-
sociated immune complex deposition in glomeruli has been
reported in several patients with malignancy, but in whom
MGN was in fact not present. Olson et al studied a patient with
malignant melanoma, mild renal insufficiency, and an underly-
ing membranoproliferative glomerulonephritis [30]. In this pa-
tient, serum and renal elution studies showed evidence of
specific complexes of melanoma—associated antigens and anti-
body. Pascal and Solvin reported a single patient with gastric
carcinoma but without apparent clinical renal disease who had
both CEA and apparent CEA-specific antibody demonstrable in
his kidney [311. The glomerular lesion in this case was one of
nonspecific mesangial and subendothelial—dense deposits. Fi-
nally, Ozawa et al studied three patients with renal cell carci-
noma in whom immunoglobulin eluates from both uninvolved
renal tissue and tumor tissue were shown to be reactive with
antigens which could be localized to proximal tubular brush
border [321. Two of these three patients had similar antibody
and antigens in the circulation. This was interpreted as indica-
tive of a subclinical nephropathy due to circulating and depos-
ited tumor associated immune complexes. Others, however,
have not found tumor—specific immune reactants or antigens in
patients with renal cell carcinoma and MGN [33].
Other antigens that have been incriminated in cancer—associ-
ated MGN are viral antigens or autologous nontumor antigens.
One study has found antibody reactive only to non-specific
nuclear antigens in a patient with MGN and bronchial carci-
noma [34]. A case of Hodgkin's disease in a child with nephrotic
syndrome due to focal glomerulosclerosis, and concurrent
Herpes zoster, was found to have virus—like particles present in
glomeruli by electron microscopy [35]. Attempts to demon-
strate renal deposits of specific Herpes antigens were not
successful in this case.
In summary, although it seems likely that cancer—associated
MGN, akin to idiopathic MGN, is immune complex—mediated,
the limitations of the immunological studies quoted above, the
high prevalence of circulating immune complexes, and the
frequent deposition of nonpathogenic glomerular immune reac-
tants in patients with cancer have made it difficult to pinpoint
tumor—associated antigens as the primary initiators of glomer-
ular injury. The alternative or additional explanation that ma-
lignancies, perhaps by affecting immune function or regulation,
render the cancer patient more susceptible to the development
of immune complex nephritis to exogenous or endogenous
antigens is equally plausible. Current work on the pathogenesis
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of experimental membranous or membranous—like GN induced
by chemical agents (mercuric chloride) or immunological inter-
ventions (graft verus host disease) suggest that defects in
immune regulation, in susceptible strains of animals, underlie
the induction of antibodies to exogenous or endogenous anti-
gens in these experimental models [36, 37]. Similarly, data on
human idiopathic MGN suggest both increased susceptibility to
the disease in individuals with certain haplotypes, such as, B8
and DR3, [38, 39] as well as alterations in lymphocyte subpop-
ulations indicative of abnormalities in immune function [40, 41].
The increased incidence of MGN in cancer patients may then
reflect an influence of cancer on these determinants of the
pathogenesis of membranous immune complex nephritis, but at
present no specific examination of this issue has been made.
Minimal change glomerulopathy and Hodgkin's disease
The review by Eagen and Lewis considered 63 cases of
nephrotic syndrome associated with Hodgkin's disease and
noted a changing pathologic spectrum whereby minimal change
disease (MCD) had replaced amyloidosis as the most significant
associated glomerular lesion [1]. A follow—up survey of 46 renal
biopsies from patients with Hodgkin's disease and nephrotic
syndrome diagnosed after 1967 revealed that 33 had minimal
change disease [13]. At least five cases have exhibited focal and
segmental glomerulosclerosis, a finding compatible with current
notions that place some forms of primary focal and segmental
glomerulosclerosis within a spectrum of diseases including
MCD [35, 42—44]. Occasional case reports continue to describe
proliferative lesions with immune complex deposition [45, 461,
and a single case of antiglomerular basement membrane disease
was described in a patient with inactive Hodgkin's disease,
possibly associated with concurrent Herpes zoster infection
[471. No particular subset of Hodgkin's disease patients as
defined by age, sex, or tumor stage has been shown to be either
particularly susceptible or resistant to glomerular injury [48].
Several of the studies have emphasized the temporal relation-
ship between the appearance of proteinuria and the presence
and activity of the Hodgkin's disease, as well as regression of
the glomerular disease after radiation or chemotherapy [1, 45].
Recently, however, Shapiro et al reported lipoid nephrosis in
two patients nine and 11 years after successful treatment of
Hodgkin's disease, with no evidence whatsoever of recurrent
malignancy [49]. Both patients, however, exhibited a decrease
in T4 (helper) cells and an increase in T8 (suppressor) cells in
their blood, findings which are known to persist in patients with
Hodgkin's disease in long—lasting remission [50].
Although the association of idiopathic nephrotic syndrome
with Hodgkin's disease is well—established, it remains nonethe-
less rare. In two large series surveying over 1,700 patients with
Hodgkin's disease, only seven patients had MCD [6, 51]. It
seems clear that the glomerular lesion is unrelated to direct
infiltration of the kidney, a frequent pathologic occurrence in
lymphoproliferative and leukemic disorders which has surpris-
ingly little effect on either renal function or glomerular perme-
ability [52, 53].
Several hypotheses have been offered to explain this rare
association. Most attempt to link an ill—defined defect in T
lymphocyte function, known to be present in patients with
Hodgkin's disease, with the elaboration of proteases or
lymphokines that alter the permselectivity characteristics of the
glomerular basement membrane [2, 46, 48, 54, 55]. To date,
however, a scientific basis for such a scenario has not emerged.
Immune deficiency states in humans affecting any of the major
components of the immune system are not generally associated
with specific glomerulopathies. The one exception is the recent
description of focal and segmental glomerulosclerosis in some
patients with the acquired immunodeficiency syndrome [56,
57]. The few reports of induction of proteinuria in experimental
animals by injection of serum of patients with MCD have not
been substantiated, and at any rate have not included patients
with Hodgkin's disease. The syndrome bears some resem-
blance to that occurring in patients receiving nonsteroidal
antiinflammatory agents in which MCD and hypersensitivity
interstitial nephritis occur simultaneously. Under these condi-
tions, it has been postulated that loss of the immunoregulatory
functions of arachidonic acid metabolites contributes to the
increased glomerular permeability [581. The effects of a number
of well—characterized lymphokines, monokines, and other im-
munoregulatory molecules are now being examined, and efforts
directed at linking such substances to glomerular alterations
may eventually clarify the pathogenesis of the nephrotic syn-
drome in Hodgkin's disease.
The presence of functionally significant glomerular disease in
other forms of leukemia and lymphoma is sufficiently rare and
the glomerular lesions described are sufficiently diverse as to
cast doubt at a clear—cut association between non-Hodgkin's
lymphoma, leukemia, and glomerulonephritis. We have identi-
fied less than 20 reported cases associating any form of non-
Hodgkin's lymphoma with clinically significant glomerular dis-
ease (Table 1) [2, 10, 35, 59—70]. Only two patients actually had
minimal change disease [2, 59]. Lymphomas of both B and T
cell origin have been described in patients with the nephrotic
syndrome.
There have been several studies of the prevalence of glomer-
ular lesions in patients with lymphoma at autopsy, Pascal found
no histologic glomerulonephritis by light microscopy in any of
31 patients studied [711, but Sutherland and Mardiney found
evidence of immune complex deposition in histologically nor-
malglomeruli in nine of 94(11%) patients with either lymphoma
or leukemia, and further suggested these complexes were
related to an oncornavirus—related antigen in two patients [72].
Gupta found a variety of glomerular abnormalities in six of 10
patients with lymphoma, two of whom also showed glomerular
deposition of immune reactants [73]. The presence of concur-
rent infections or other complicating clinical conditions were
not described for any of these patients. Finally, Oldstone et al
eluted antibody bound to glomerular basement membranes in
two patients with Burkitt's lymphoma and found reactivity to
Epstein—Barr virus antigens [74]. No information as to the renal
function in these two patients was provided. Experimental
studies have shown a high incidence of glomerulonephritis in
virally—associated hematopoietic malignancies induced by fe-
line leukemia virus and numerous murine oncornaviruses [75,
76]. This evidence suggests that patients with lymphomas may
be exposed to a variety of immunologically recognizable anti-
gens which may include tumor—related viruses, concurrent
infections, and other less easily characterized substances. In
view of the common involvement of the glomerulus in many
immune—complex mediated processes, it seems striking how
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Table 1. (ulomerular lesions in patients with non-Hodgkin's
lymphoma'
Lymphoma Renal lesion
Minimal change disease
Crescentic glomerulonephritish
Proliferative glomerulopathy5
Membranoproliferative gb-
merulonephritis
Membranous glomerulone-
phritis
Membranous glomerulopathy5
Minimal change disease
Crescentic glomerulonephri-
tis with immune deposits
Crescentic glomerulonephri-
tis with rare deposits of
immune reactants
Proliferative glomerulone-
phritis with immune de-
posits
IgA nephropathy
IgA nephropathy
Mild mesangial proliferative
glomerulopathy vs. focal
and segmental glomeru-
losclerosis
Membranoproliferative gb-
merulonephritis
Membranoproliferative gIn-
merulonephritis
Crescentic glomerulonephri-
tis without immune de-
posits
Crescentic glomerulonephri-
tis
Crescentic glomerulonephri-
tis
19 70 T-cell lymphoblastic Focal glomerulosclerosis
Abbreviations are: NOS, not otherwise specified; WDLL, well—
differentiated lymphocytic lymphoma; PDL, poorly—differentiated lym-
phocytic lymphoma.
Light—microscopic diagnosis only.
well the glomerulus remains protected from clinically significant
immune injury in this patient population.
The association of glomerulopathies with leukemia is similar
to that of non-Hodgkin's lymphoma; it is cited more often than
reported. There are less than twenty-five reported cases; most
of the affected patients had chronic lymphocytic leukemia
(CLL) (Table 2) [15, 77—921. Although there is some diversity in
the underlying glomerular lesions, many of the patients with
CLL had membranoproliferative gbomerubonephritis; several
had amyloidosis only. We found reports of only two cases of
nonlymphoid hematopoietic malignancy with a concurrent
glomerulopathy [91, 921.
Associations of glomerulopathies with non-neoplastic lym-
phoid proliferations have recently been recorded. Two patients
with angiofollicular lymph node hyperplasia and nephrotic
syndrome were found to have minimal change disease and
membranous glomerulonephritis, respectively [93. 94]. Two
patients with angioimmunoblastic lymphadenopathy and acute
oliguric renal failure were found to have gbomerulonephritis
with deposition of immune reactants [951. A review of 220
patients with sinus histiocytosis and massive lymphadenopathy
uncovered three patients with clinical evidence of glomerulo-
Case Ref. Leukemia Renal lesion
1
2
77
77
CLL
CLL
Capillary wall thickening5
Amyloidosis"
3 78 CLL Amyloidosis5
4 79 CLL Focal glomerulosclerosis1'
5 80 CLL Minimal change disease5
6 81 CLL Membranoproliferative glomerulonephritis
7 81 CLL Focal Proliferative glomerulonephritis with
immune deposits
8 82 CLL Proliferative and scierosing glomerulopathy'
9 15 CLL Membranous glomerubonephritis
it) 83 CLL Membranoproliferative glomerulonephritis
11 83 CLL Membranoproliferative glomerulonephritis
12 84 CLL Membranoproliferative glomerulonephritis
13 85 CLL Membranoproliferative glomerulonephritis
14 86 CLL Membranous glomerulonephritis
15 87 CLL Membranoproliferative glomerulonephritis
16 88 CLL Focal glomerulosclerosis
17 89 CLL Minimal change disease
18 89 CLL Membranoproliferative glonicrulonephritis
19 89 CLL Membranoproliferative glomerubonephritis
20 89 CLL Minimal change disease
21 90 HCL Amyloidosis
22 91 CML Minimal change disease
23 92 AMML Focal sclerosis with mesangial immune de-
posits
a Abbreviations are: CLL, chronic lymphocytic leukemia: CML,
nephritis 1961. Both patients in whom renal tissue was examined
by light microscopy had crescentic gbomerulonephritis.
Lymphoplasinacytic disorders
The spectrum of glomerulopathies seen in the various
dysproteinemias has been the subject of intensive recent study.
Classically the renal lesions of excess immunogbobulin produc-
tion have been typified by the "myeloma kidney," in which the
prominent lesion is that of a tubular cast nephropathy with
associated tuhulointerstitial nephritis [97, 98]. Until approxi-
mately ten years ago, the glomerular lesions seen in dyspro-
teinemia were thought to be limited either to associated
amyloidosis, which occurs inS to 20% of patients with multiple
myeloma or Waldenstrom's macrogbobulinemia [97—100], or to
secondary changes consequent to severe tububointerstitial in-
jury. The lesions of amyloidosis have been reviewed elsewhere
[97, 1011 and will not be considered further.
With the availability of antisera against light chain compo-
nents, a nonamyloidotic gbomerubopathy associated with depo-
sition of light chains or apparent monocbonal immunoglobulins
has been recognized in myeboma and in related plasma cell
dyscrasias [102—104]. Initially described as a nodular glomeru-
bosclerosis resembling the lesions of Kimmelstiel—Wilson dis-
ease, these lesions were found by immunofluorescence micros-
copy to contain deposits of light chains, most often kappa
chains, and were frequently associated with similar deposition
along tubular basement membranes. More recent experience
has shown that the pathologic spectrum of these lesions is more
heterogeneous than first described, with morphologic patterns
of mesangiocapillary glomerubonephritis, proliferative gbomer-
ulonephritis, crescentic glomerulonephritis, and even minimal
Table 2. Gbomerular lesions in patients with leukemiaa
Case Ref.
1 59 Lymphosarcoma, NOS
2 60 WDLL
3 61 Lymphosarcoma, NOS
4 35 Burkitt's lymphoma
5 10 Lymphosarcoma, NOS
6 62 Lymphosarcoma, NOS
7 2 WDLL
8 63 WDLL
9 63 PDL
10 13 WDLL
11 64 Mycosis fungoides
12 64 Mycosis fungoides
13 65 T-cell lymphoma, NOS
14 66 Lymphoma, NOS
15 67 WDLL
16 68 Lymphocytic lymphoma,
NOS
17 69 Lymphocytic lymphoma,
NOS
18 69 WDLL
chronic myelogenous leukemia; AMML. acute myelomonocytic leuke-
mia: HCL, hairy cell leukemia.h Light microscopic diagnosis only.
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change glomerulopathy 1103—1121. Similarly, immunofluores-
cence studies have revealed cases showing deposition of light
chains alone or with an associated heavy chain component [107,
108, 111]. This has led to suggestions that light chain nephrop-
athy is best considered as monoclonal immunoglobulin deposi-
tion disease (MIDD) [107, 108, lii]. Ultrastructural features
may also be variable, but most often are notable for deposition
of finely granular electron—dense material in areas correspond-
ing to those with light chain staining deposits by immunofluo-
rescence.
Since in some patients this renal lesion was discovered at the
same time or even preceding more usual clinical manifestations
of myeloma, the question arises as to whether all patients with
light chain nephropathy should be regarded as premyelomatous
even in the absence of overt signs of myeloma. Cases have been
described in which lymphoma has developed as late as four
years after the diagnosis of characteristic glomerular lesions
[1121. Evidence of a plasma cell dyscrasia was obtained in some
patients by demonstration of the monoclonal nature of cultured
bone marrow cells, but such techniques are not usually avail-
able for diagnosis [103, 1071. Autopsy studies of some, but not
all, cases have shown systemic light chain deposition in such
organs as livers, lung, spleen, brain, and heart [113, 1141.
Nevertheless, it is frequently difficult to demonstrate parapro-
teins either in serum or urine of these patients, and approxi-
mately half of these patients fail to show evidence of a
lymphoplasmacytic disorder even after extended clinical
follow—up ranging up to seventeen years [103, 106, 107, 1111.
On balance, it appears that while individual cases of MIDD
may not necessarily be accompanied by plasma cell neoplasia,
the prevalence of lymphoplasmacytic dyscrasias in this group of
patients is sufficiently high that such patients should have a
careful evaluation for occult lymphoid malignancy. This
work—up should include serum and urine immunoelectropho-
resis and a bone marrow examination that is evaluated at a
center capable of performing immunohistochemical or lym-
phoid marker studies that might delineate monoclonal B-cell
proliferations not recognized by microscopic morphology
alone.
Hypotheses concerning the mechanisms by which glomerular
injury may be associated with light chain deposition of a single
subclass have principally focused on physicochemical explana-
tions involving either trapping of structurally abnormal light
chains within glomeruli or deposition of excess serum light
chains as might occur in multiple myeloma. However, deposi-
tion on the basis of immunologic binding has not been excluded.
Studies have included attempts to demonstrate antibody bind-
ing to renal parenchyma of laboratory animals using sera from
affected patients [1061, and structural and kinetic studies of
immunoglobulin synthesis by bone marrow cells of patients to
identify unbalanced or abnormal immunoglobulin production
[103, 1071. A unifying mechanism has not emerged from these
studies. Additional hypotheses that have yet to be tested
include intrinsic abnormalities of the affected kidneys which
might selectively bind restricted classes of light chains or
immunoglobulins, and unusal antigenic (non-neoplastic) stimu-
lation of a single plasma cell clone with subsequent deposition
of monoclonal immunoglobulin.
The pathogenesis of the multifaceted clinical and pathologic
manifestations of nephrotoxicity associated with light chains or
monoclonal immunoglobulins in the related setting of multiple
myeloma is likewise only beginning to be explored. It remains
difficult to explain why some patients with myeloma may
develop no apparent renal disease, while others develop such
different lesions as amyloidosis, glomerulonephritis, systemic
tissue deposition of immunoglobulin, cast nephropathy, or renal
tubular defects. Most studies of this issue have focused on a
central pathogenic role for Bence—Jones proteins (light chains).
It is well known that Bence—Jones proteins differ in their
nephrotoxic potential, and that some patients with significant,
long—standing Bence—Jones proteinuria may not develop evi-
dence of renal dysfunction [1151. This variability in nephrotoxic
potential extends to experimental models, whereby only some
of the Bence—Jones proteins isolated from patients with
myeloma produce cast nephropathy when injected into mice
[116]. This has been ascribed to physicochemical features of the
individual light chains, including increased interaction and
co-precipitation with Tamm—Horsfall protein in an acid envi-
ronment [117] and to molecular charge. Evidence that
Bence—Jones proteins with high isoelectric points are more
susceptible to formation of myeloma casts has been reported by
some investigators [118] and disputed by others [119, 120];
while probably of some importance, the evidence suggests that
the isoelectric point of light chains alone is insufficient to
account for mechanisms of light chain cast nephropathy. A
recent clinical study of 17 patients with multiple myeloma has
suggested that less anionic or neutral monoclonal light chains
were likely to cause cast nephropathy and renal insufficiency,
while more negatively—charged light chains were more likely to
result in glomerular and tissue deposition, perhaps because of
greater hindrance in glomerular filtration of negatively—charged
light chains [121]. Experimental studies to test this hypothesis
have yet to be performed.
The intrinsic structure of monoclonal proteins may also be a
determinant of pathogenicity. Lambda light chains are associ-
ated with amyloid formation more frequently than kappa
chains. Experimental studies have shown that only 15 to 20% of
light chains are amyloidogenic after proteolytic digestion, with
the preponderance of amyloidogenic light chains being of
lambda type [101, 122]. A light chain protein structure that is
either amyloidogenic or susceptible to certain forms of in situ
proteolysis may then be critical in determining whether there is
tissue deposition as amyloid deposits. Other hypotheses, as yet
untested, have related the renal deposition of paraproteins to
abnormalities of glycosylation, size, or polymerization [102,
121].
Specific forms of glomerular injury may also be seen in three
other dysproteinemias. Cryoglobulinemia commonly occurs in
lymphoid malignancies, and a characteristic cryoglobulin—as-
sociated glomerulonephritis may develop. The latter is mani-
fested clinically by vasculitis, hypocomplementemia, and acute
or subacute renal insufficiency with hematuria, and histologi-
cally by proliferative and exudative changes, deposition of
eosinophilic material in basement membranes and occasional
eosinophilic intracapillary thrombi [97, 123, 124]. The thrombi
are usually strongly reactive for 1gM and IgG by immunofluo-
rescence microscopy. Waldenstrom's macroglobulinemia is as-
sociated with infiltration of the renal parenchyma by neoplastic
cells in over 50% of cases, but this infiltration is generally not
accompanied by clinically evident renal dysfunction [97, 98,
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1001. A distinctive glomerulopathy also occurs in some patients
characterized by intracapillary deposition of eosinophilic mate-
rial which contains 1gM with a light chain component similar to
the circulating paraprotein [1001. The glomerular lesion, seen in
about one—third of patients studied by renal biopsy or at
autopsy, does not correlate with disordered renal function.
Occasional cases of immune complex glomerulonephritis and
nodular glomerulosclerosis have also been reported in such
patients [108. 125]. Finally, there have been several recent
reported cases of monoclonal gammopathies associated with a
rapidly progressive glomenilonephritis that is not mediated by
concurrent cryoglobulinemia. These will be discussed further
below.
Rapidly progressive glomerulonephritis
Rapidly progressive (crescentic) glomerulonephritis (RPGN)
is an infrequent glomerular lesion which is said to account for
approximately 1 to 2% of cases of glomerulonephritis in most
centers [1261. Systemic diseases, including vasculitis, lupus
erythematosus, and Goodpasture's syndrome can be implicated
in some cases of RPGN, and recently a small number of reports
have demonstrated an apparent association with lymphoplas-
macytic disorders and other malignancies.
The most extensive of these reports surveyed the prevalence
of patients with malignancy among two series of patients with a
pathologic diagnosis of crescentic glomerulonephritis (GN).
These studies showed that four of 60 (7%) and seven of 80 (9%)
patients with crescentic GN also had a malignancy [68, 127]. To
these may be added five additional cases of RPGN reported in
patients with lymphoma [60, 63, 69]. The strength of the
association recorded is subject to some reservations. At least
two patients had concurrent vasculitis as a possible alternate
etiology for crescentic glomerulonephritis [69]. Almost half of
the RPGN patients in the series of Whitworth et al had
cryoglobulinemia which may cause crescentic glomerulonephri-
tis; whether these included the patients with malignancies is not
stated [127]. Of the seven patients reported by Biava et al, only
one had RPGN prior to the diagnosis of malignancy [681. The
remaining six patients developed RPGN over a period of four
months to three years after the tumor was first diagnosed, and
so the consequences of tumor therapy and altered host response
to infections and other mediators of disease remain a compli-
cating factor in determining the significance of the association.
Similar considerations also apply to the cases reported by
Whitworth et al, The cases of Sage!, Muller and Logan, and
Petzel et al demonstrating virtually simultaneous presentation
of RPGN and lymphonia provide the strongest evidence of this
rare association [60, 631. The extent of immunofluorescent
evaluation of the renal lesions has varied, but reported findings
indicate heterogeneous pathogenetic mechanisms for the renal
disease. One case of carcinoma and at least one case of
lymphoma had apparent immune complex—mediated glomeru-
lonephritis [63, 1271. Ten cases had no significant deposits by
immunofluorescence or electron microscopy and four were not
adequately evaluated.
There also have been seven cases reported of RPGN in
patients with monoclonal gammopathies [110, 128—131]. Only
one of these had definite evidence of myeloma [1101. There was
no predominant immunoglohulin subclass. In those patients in
which immunofluorescence and ultrastructural studies were
performed, some patients had no deposits by immunofluores-
cence, others had immune deposits differing from the circulat-
ing paraprotein, and only two of four studied had apparent
glomerular deposition of the paraprotein. Given the diversity of
patterns of injury exhibited, a direct association between mono-
clonal gammopathies and RPGN remains uncertain.
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